Renovus-backed ToxStrategies completed the acquisition of Clintrex.

Renovus-backed ToxStrategies, a multidisciplinary scientific consulting firm, completed the acquisition of Clintrex, a scientific, clinical trial, operational, and regulatory assistance provider. Financial terms were not disclosed. “We are delighted to partner with ToxStrategies and its associated companies. This partnership will enable us to provide a combined approach for assisting biotech and pharmaceutical companies in their development programs. This approach will include preclinical toxicology, health outcome and epidemiologic approaches, in addition to the basic science, clinical trial, operational and regulatory assistance we currently provide. Together, we believe this will facilitate the development process and increase the likelihood that promising new therapies will become available to help patients with these disorders,” Dr. C. Warren Olanow, Clintrex CEO.